EMA: EC Decision — New Marketing Authorisation — Pavblu (aflibercept)

EMA14 Apr 2026·EC Decision — New Marketing Authorisation● 6/10i

EMA: EC Decision — New Marketing Authorisation — Pavblu (aflibercept)

Amgen Technology (Ireland) UC

The European Commission approved aflibercept (Pavblu, Amgen) for neovascular age-related macular degeneration, visual impairment from retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization on April 14, 2026. This represents a new marketing authorization following CHMP positive opinion in January 2025. The approval establishes Amgen's entry into the competitive anti-VEGF ophthalmology market, challenging established players Regeneron/Bayer (Eylea) and Roche (Lucentis/Vabysmo) across multiple retinal indications.

Strategic signal

Amgen's EU approval creates a third major anti-VEGF competitor in ophthalmology, potentially pressuring Regeneron's Eylea franchise which dominates wet AMD and diabetic macular edema markets. European ophthalmologists now have increased leverage in pricing negotiations, particularly in Germany where G-BA assessments favor therapeutic alternatives. This follows the typical EU ophthalmology adoption pattern where biosimilars and new entrants gain traction through hospital tender processes before expanding to outpatient settings.

OtherAmgen Regeneron Bayer Roche

Original Abstract

EMA action: EC Decision — New Marketing Authorisation | Medicine: Pavblu | INN (active substance): aflibercept | Decision date: April 14, 2026 | CHMP opinion: January 30, 2025 | EC decision: April 14, 2026 | Sponsor: Amgen Technology (Ireland) UC | EMA product number: EMEA/H/C/006339 | Revision: 2 | Indication: Pavblu is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), visual impairment due to diabetic macular oedema (DME) (see section 5.1), visual impairment due to myopic choroidal neovascularisatio | Geography: European Union (EMA / EC)

View original source ↗

Related signals

ClinicalTrials17 Apr 2026·Phase 3● 8/10iHigh impact

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Phase 3 trial evaluating retatrutide for chronic low back pain in people with obesity or overweight, targeting dual primary endpoints of pain intensity reduction and weight loss. 586-person placebo-controlled study expected to complete September 2027, investigating a novel indication beyond traditional metabolic endpoints. Eli Lilly is exploring pain management as a potential expansion for their triple agonist, representing the first major trial of a GLP-1-based therapy specifically for chronic pain conditions.

GLP-1Weight lossOtherEli Lilly

PubMed16 Apr 2026·European heart journal● 7/10i

PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study.

PCSK9 inhibitor monoclonal antibodies reduced major cardiovascular events by 31% versus standard care in people with atherosclerotic cardiovascular disease but without prior ischemic events. Real-world observational study using US claims data, 19,670 patients followed for 5 years with propensity score matching. This provides the first large-scale real-world evidence for PCSK9 inhibitors in primary prevention within high-risk ASCVD populations, extending beyond the clinical trial evidence that has driven current guidelines. The observational design limits causal inference compared to randomized controlled trials.

PCSK9CardiovascularReal-world evidenceAmgen Regeneron

ClinicalTrials14 Apr 2026·Phase 3● 7/10i

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes

RO7795068, a dual GLP-1/GIP receptor agonist from Roche, is being tested versus placebo for weight management in people with obesity or overweight and type 2 diabetes. Phase 3 trial targets 1,600 participants over 72 weeks in a randomized, double-blind, placebo-controlled design. This positions Roche to compete directly with Eli Lilly's tirzepatide (Mounjaro/Zepbound) in the dual incretin mechanism space across both diabetes and obesity indications. The trial represents Roche's first major entry into the competitive GLP-1 obesity market dominated by Novo Nordisk and Eli Lilly.

GLP-1Weight lossType 2 diabetesDrug comparisonsHoffmann-La Roche Eli Lilly

ClinicalTrials20 Mar 2026·Phase 3● 7/10i

A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Orforglipron is being tested in women with stress urinary incontinence who have obesity or overweight in two phase 3 studies under a master protocol. The trials will enroll 1,000 participants with 58-week follow-up, comparing daily oral orforglipron to placebo. This represents a novel indication expansion for Eli Lilly's small-molecule GLP-1 beyond diabetes and weight management, targeting a large underserved population where weight loss could provide therapeutic benefit. This marks the first major GLP-1 trial in urological conditions, potentially opening a new market segment.

GLP-1OtherEli Lilly